317 related articles for article (PubMed ID: 21393611)
41. Segmental glomerulosclerosis in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril.
Jeong HJ; Kim YS; Kwon KW; Kim MS; Kim S; Choi KH; Lee HY; Han DS; Park K
Clin Transplant; 2003 Apr; 17(2):108-13. PubMed ID: 12709075
[TBL] [Abstract][Full Text] [Related]
42. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
[TBL] [Abstract][Full Text] [Related]
43. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort.
Bellur SS; Troyanov S; Cook HT; Roberts IS;
Nephrol Dial Transplant; 2011 Aug; 26(8):2533-6. PubMed ID: 21273233
[TBL] [Abstract][Full Text] [Related]
44. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
Horita Y; Tadokoro M; Taura K; Suyama N; Taguchi T; Miyazaki M; Kohno S
Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
[TBL] [Abstract][Full Text] [Related]
45. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
[TBL] [Abstract][Full Text] [Related]
46. High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
Rasche FM; Keller F; Lepper PM; Aymanns C; Karges W; Sailer LC; Müller Lv; Czock D
Clin Exp Immunol; 2006 Oct; 146(1):47-53. PubMed ID: 16968397
[TBL] [Abstract][Full Text] [Related]
47. Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes.
Mizerska-Wasiak M; Małdyk J; Pańczyk-Tomaszewska M; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Firszt-Adamczyk A; Stankiewicz R; Bieniaś B; Zajączkowska M; Gadomska-Prokop K; Grenda R; Miklaszewska M; Pietrzyk J; Pukajło-Marczyk ; Zwolińska D; Szczepańska M; Demkow U; Roszkowska-Blaim M
Adv Exp Med Biol; 2015; 873():79-86. PubMed ID: 26269025
[TBL] [Abstract][Full Text] [Related]
48. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy.
Tsuboi N; Kawamura T; Miyazaki Y; Utsunomiya Y; Hosoya T
Nephrol Dial Transplant; 2011 Nov; 26(11):3555-60. PubMed ID: 21771759
[TBL] [Abstract][Full Text] [Related]
49. Predictors of Progression in IgA Nephropathy in Childhood.
Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
[TBL] [Abstract][Full Text] [Related]
50. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
[TBL] [Abstract][Full Text] [Related]
51. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
Zhang Q; Shi SF; Zhu L; Lv JC; Liu LJ; Chen YQ; Zhang H; Wang HY
Am J Nephrol; 2012; 35(4):312-20. PubMed ID: 22456060
[TBL] [Abstract][Full Text] [Related]
52. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
[TBL] [Abstract][Full Text] [Related]
53. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease.
Lundberg S; Lundahl J; Gunnarsson I; Jacobson SH
Clin Nephrol; 2010 Mar; 73(3):221-8. PubMed ID: 20178722
[TBL] [Abstract][Full Text] [Related]
54. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
55. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
56. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.
Takahashi Y; Satoh M; Minami Y; Tabuchi T; Itoh T; Nakamura M
Clin Sci (Lond); 2010 Jul; 119(9):395-405. PubMed ID: 20524934
[TBL] [Abstract][Full Text] [Related]
57. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
[TBL] [Abstract][Full Text] [Related]
58. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
[TBL] [Abstract][Full Text] [Related]
59. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.
Elung-Jensen T; Heisterberg J; Sonne J; Strandgaard S; Kamper AL
Eur J Clin Pharmacol; 2005 Apr; 61(2):87-96. PubMed ID: 15761754
[TBL] [Abstract][Full Text] [Related]
60. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.
Remuzzi A; Perico N; Sangalli F; Vendramin G; Moriggi M; Ruggenenti P; Remuzzi G
Am J Physiol; 1999 Mar; 276(3):F457-66. PubMed ID: 10070170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
